What science can do

We are a global, science-led, patient-focused pharmaceutical business, committed to excellence in the research, development and commercialisation of prescription medicines.

Our differentiated and growing portfolio of approved medicines, global reach and rich R&D pipeline give us confidence that we will continue to grow faster than the industry over the near and medium term.

Michel Demaré, Chair, AstraZeneca

Our vision for health is not a short-term one. While maintaining our focus on discovering new small and large molecules, we are also increasing investment behind new modalities…

Pascal Soriot, Chief Executive Officer, AstraZeneca


Strategic overview

Inspired by our Values and what science can do, we are focused on accelerating the delivery of life-changing medicines that create enduring value for patients, society, the planet and our shareholders.

Our ambition is to launch at least 15 new medicines by 2030. Three were approved in 2023.

Achievements in 2023:


regulatory events

We achieved 56 regulatory events, either submissions or approvals for our medicines in major markets, including three first new molecular entity (NME) approvals. We also achieved 30 pipeline progression events, either NME Phase II starts or Phase III investment decisions.

Achievements in 2023:


Total Revenue

Total Revenue increased by 3% (6% at CER) to $45,811 million. Total Revenue, excluding COVID-19 medicines, increased 13% (15% at CER) to $45,488 million.

Achievements in 2023:


Employee belief that AstraZeneca is a great place to work

We continued to invest in our people in 2023, ensuring we recruit, retain and develop a talented workforce. Our Ambition Zero Carbon strategy also delivered further reductions in our greenhouse gas emissions across the value chain.


Our therapy area focus

We are focused on therapy areas where we can make the most meaningful difference to patients.

With a focus on patients, we have a global reach and a diversified portfolio of medicines across primary care, specialty care and rare diseases.


Our commitment to people

We attract, retain and develop talented individuals by cultivating a great place to work that values and rewards innovation, entrepreneurship and outstanding performance.


Our commitment to society

We want to secure a future where all people have access to affordable, sustainable and innovative healthcare.


Our commitment to the planet

Science-led climate action and investments in nature and biodiversity are vital to improving health outcomes and proactively managing our environmental impact.

Near-term target:

98% absolute reduction in Scope 1 and 2 GHG emissions by 2026 from 2015 baseline:

We are accelerating the delivery of net-zero healthcare and our progress towards net zero. We were one of the first companies to have our net-zero targets across Scope 1, 2 and 3 verified under the Science Based Targets initiative Net-Zero Corporate Standard.

Achievements in 2023:


Reduction in Scope 1 and 2 GHG emissions since 2015.
(2022: -59.3% reduction).

Near-term target:

Launch first next-generation respiratory inhalers with near-zero climate impact propellant from 2025.

We continued to focus on the next-generation propellant transition for pMDI products in our respiratory portfolio. They are strategically important to our business and a key product-related element of Ambition Zero Carbon.

Achievements in 2023:


Safe API discharges for AstraZeneca sites and 94% safe API discharges for globally managed first-tier supplier sites.

Near-term target:

Reduce energy consumption by 10% and double energy productivity (EP100) from 2015 to 2025.

We are investing in nature to benefit planetary and societal health, while working towards sustainable resource use, water security, and halting and reversing biodiversity loss.

Achievements in 2023:


Reduction in energy consumption since 2015.


Our performance

2023 was a year of strong growth and execution of our long-term growth strategy.

Net cash flow from operating activities


Up 5% at actual rate of exchange to $10,345 million
(2022: $9,808 million)

Reported EPS


Increase in Reported EPS to $3.84
(2022: $2.12)

Core EPS


Up 9% at actual rate of exchange to $7.26
(up 15% at CER)
(2022: $6.66)

• Used for remuneration of Executive Directors